{"id":250743,"date":"2022-11-02T00:00:00","date_gmt":"2022-11-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/biosbi0001-2022-biopharma-biosimilars-current-treatment-biosimilars\/"},"modified":"2026-03-31T10:38:21","modified_gmt":"2026-03-31T10:38:21","slug":"biosbi0001-2022-biopharma-biosimilars-current-treatment-biosimilars-current-treatment-landscape-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0001-2022-biopharma-biosimilars-current-treatment-biosimilars-current-treatment-landscape-us-eu\/","title":{"rendered":"Biosimilars &#8211; Current Treatment &#8211; Biosimilars | Current Treatment | Landscape | US\/EU"},"content":{"rendered":"<p>In the last decade, the biosimilar therapy market has been growing, led mainly by two therapeutic areas: immunology and oncology. It now continues to expand into new fields. To enhance this growth, it is especially relevant to understand physicians\u2019 perceptions of currently available biosimilars, elucidate their decision-making process, and determine the most relevant attributes a biosimilar should have. Based on Clarivate\u2019s primary market research in the United States, France, and Germany with physicians from six specialties (gastroenterologists, endocrinologists, nephrologists, rheumatologists, medical oncologists, and hematologist-oncologists), our clients will better understand physicians\u2019 experience with and attitude toward biosimilars and understand the evolution of biosimilars over the last three years (2020, 2021, and 2022).<\/p>\n<p><strong>Questions answered in this report: <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><!--[endif]--><b>Understand current biosimilar use. <\/b>What are the current levels of prescribing biosimilars among physicians from different specialties? How do physicians perceive current biosimilars?<\/li>\n<li><b>Understand the drivers, barriers, and physician attitudes regarding biosimilar uptake. <\/b>What are the greatest drivers of\/barriers to biosimilar use? How familiar with biosimilars are physicians from different specialties? How similar do physicians perceive biosimilars and reference brands to be? Are physicians aware of the pharmacy-level substitution rules in their own country, and would they expect to prevent this substitution? What are physicians\u2019 opinions of indication extrapolation?<\/li>\n<li><b>Future use. <\/b>Which types of biosimilar manufacturers do physicians trust most? How will physicians adopt biosimilars initially, and will adoption vary by specialty? Will physician uptake be affected by biosimilar price\/reimbursement policies? Will physicians use new biologics, depending on their profile, once biosimilars are available? How will physicians choose between multiple biosimilars of the same reference product?<\/li>\n<\/ul>\n<p><strong>Scope <\/strong><\/p>\n<p><strong>Markets covered:<\/strong> United States, France, and Germany.<\/p>\n<p><strong>Primary research: <\/strong>Online quantitative survey of 550 physicians from six specialties\u2014endocrinologists (90), gastroenterologists (92), nephrologists (91), rheumatologists (90), hematologist-oncologists (98), and medical oncologists (89).<\/p>\n","protected":false},"template":"","class_list":["post-250743","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250743","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250743\/revisions"}],"predecessor-version":[{"id":282941,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250743\/revisions\/282941"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250743"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}